

**EXTRACORPOREAL LIFE SUPPORT FOR REFRACTORY
IN-HOSPITAL AND OUT-OF-HOSPITAL CARDIAC ARREST:
ARE THE OUTCOMES REALLY DIFFERENT?
A 10-YEAR EXPERIENCE**

*Pozzi M¹, Armoiry X², Koffel C³, Pavlakovic I³, Lavigne F³, Schweizer R³, Fellahi JL³,
Hugon-Vallet E⁴, Flagiello M¹, Adamou K¹, Grinberg D¹, Generali T¹, Obadia JF¹*

¹Department of Cardiac Surgery, “Louis Pradel” Cardiologic Hospital, Lyon, France

²University of Warwick, Warwick Medical School, Division of Health Sciences, Coventry, England

³Department of Anesthesia and ICU, “Louis Pradel” Cardiologic Hospital, Lyon, France

⁴Department of Cardiology, “Louis Pradel” Cardiologic Hospital, Lyon, France



CONFLICT OF INTEREST DISCLOSURE



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)

EUROPEAN ACCREDITATION COUNCIL ON CME (EACCME®)

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS
T + 32 2 649 51 64 - F + 32 2 640 37 30
<https://eaccme.uems.eu - accreditation@uems.eu>

Conflict of Interest Disclosure Form

NAME : Matteo POZZI

AFFILIATION: Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France

In accordance with criterion 14 of document UEMS 2016/20 "EACCME" criteria for the Accreditation of Live Educational Events (LEEs), all declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations also must be made readily available, either in printed form, with the programme of the LEE, or on the website of the organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement for reimbursement of expenses in relation to the LEE has been provided.

DISCLOSURE

- I have no potential conflict of interest to report
 I have the following potential conflict(s) of interest to report

Type of affiliation / financial interest Name of commercial company

Receipt of grants/research supports:

Receipt of honoraria or consultation fees:

Participation in a company sponsored speaker's bureau:

Stock shareholder:

Spouse/partner:

Other support (please specify):

Signature: *Matteo Pozzi*

Date: 23/05/2018

UEMS₀₉ – Union Européenne des Médecins Spécialistes
IBAN BE28 0001 3283 3820 | BIC (SWIFT) BPOFBEB1 | VAT n° BE 0469.067.848

CONFLICT OF INTEREST TO DISCLOSE:

None

INTRODUCTION

Refractory cardiac arrest is defined by the lack of return of spontaneous circulation within a period of at least 30 min of CPR under medical direction in the absence of pre-existing hypothermia

Riou et al.


Ann Fr Anesth Reanim 2009;28:182-90



**IN-HOSPITAL
CARDIAC ARREST
(IHCA)**

**OUT-OF-HOSPITAL
CARDIAC ARREST
(OHCA)**

INTRODUCTION



Extracorporeal CPR (eCPR) should be considered as a rescue therapy for those patients in whom initial ALS measures are unsuccessful and/or to facilitate specific interventions (e.g. coronary angiography and percutaneous coronary intervention (PCI) or pulmonary thrombectomy for massive pulmonary embolism).

INTRODUCTION

CONFERENCE REPORTS AND EXPERT PANEL



Position paper for the organization of ECMO programs for cardiac failure in adults

ECPR

Indications

- Failure to achieve ROSC despite 15 min of conventional CPR
- Cardiac arrest presumed to be of cardiac origin (including pulmonary embolism)

Contraindications

Relative

- Advanced age
- Prolonged or unknown time from onset of cardiac arrest to initiation of CPR

Absolute

- Acute aortic dissection or severe aortic insufficiency
- Underlying end-stage heart failure if long-term heart replacement therapies will not be considered
- Any non-cardiac condition or organ dysfunction that would limit the likelihood of overall benefit from ECPR, such as severe, irreversible brain injury or untreatable metastatic cancer
- Inconsistent with patient's previously expressed goals of care

BACKGROUND

ECLS for IHCA

Author	[Reference]	Patients (n.)	Survival CPC 1-2
Masseti	Ann Thorac Surg 2005;79:178-83	35	20.0%
Chen	Lancet 2008;372:554-61	59	23.7%
Shin	Crit Care Med 2011;39:1-7	85	28.2%
Bednarczyk	Resuscitation 2014;85:1713-9	22	45.4%
Peigh	J Thorac Cardiovasc Surg 2015;150:1344-9	23	30.4%
Ellouze	Artif Organs 2018;42:15-21	43	20.9%

Outcomes of ECLS for IHCA

**Satisfactory
Encouraging
Homogeneous**

Survival CPC 1-2: 20-45%

BACKGROUND

ECLS for OHCA

Author	[Reference]	Patients (n.)	Survival CPC 1-2
Le Guen	Crit Care 2011;15:R29	51	3.9%
Mégarbane	Resuscitation 2011;82:1154-61	47	2.1%
Maekawa	Crit Care Med 2013;41:1186-96	53	15.1%
SAVE-J Study	Resuscitation 2014;85:762-8	234	13.7%
Pozzi	Int J Cardiol 2016;204:70-6	68	4.4%
CHEER Trial	J Thorac Cardiovasc Surg 2015;150:1344-9	11	45.4%
Choi	Resuscitation 2016;99:26-32	320	9.1%
Rousse	Artif Organs 2016;40:904-9	32	3.1%

Outcomes of ECLS for OHCA



Survival CPC 1-2: Disappointing results

OBJECTIVE

To evaluate the results of ECLS support for refractory cardiac arrest and compare the outcomes between IHCA and OHCA patients at a single-centre experience

MATERIALS and METHODS

Study design - Patient population

Observational analysis of our prospective database



Adult patients supported with ECLS for witnessed, refractory IHCA or OHCA



01/01/1997 - 31/12/2016



449 ECLS



131 (29.2%) ECLS for refractory cardiac arrest




45 (34.4%) IHCA

86 (65.6%) OHCA

MATERIALS and METHODS

Study protocol

WITNESSED REFRACTORY CARDIAC ARREST



MATERIALS and METHODS

Implantation technique



RESULTS

Baseline characteristics

131 patients

Mean age: 43.2 ± 12.8 (18 - 76) years

Male sex: 71.8%

	OVERALL	IHCA	OHCA	<i>p-value</i>
Age, years	43.2 ± 12.8	46.2 ± 13.5	41.7 ± 12.2	0.054
Male sex, n (%)	84 (71.8)	29 (64.4)	65 (75.6)	0.179
Cardiovascular risk factors, n (%)				
Hypertension	16 (12.2)	5 (11.1)	11 (12.8)	0.780
Diabetes	10 (7.6)	6 (13.3)	4 (4.7)	0.091
Dyslipidemia	10 (7.6)	5 (11.1)	5 (5.8)	0.278
Active smoking	36 (27.5)	11 (24.4)	25 (29.1)	0.573
^a Rhythm at ECLS implantation, n (%)				0.493
Shockable rhythm	38 (29.0)	11 (26.2)	27 (32.1)	
Non-shockable rhythm	88 (67.2)	31 (73.8)	57 (67.9)	

^aCardiac rhythm at ECLS implantation was not recorded in 5 patients

RESULTS

Baseline biological profile

	IHCA	OHCA	<i>p-value</i>
BUN, mmol/l	11.2±6.9	6.3±2.3	0.001
Bilirubin, µmol/l	30.8±36.2	9.5±6.5	0.034
ASAT, U/l	1353.3±2537.0	821.8±788.8	<0.001
ALAT, U/l	851.3±1462.7	459.5±456.2	<0.001
Low-flow time, min	46.9±19.0	85.3±23.0	<0.001
Lactates	7.1±5.2	16.0±5.5	<0.001
pH	7.32±0.13	7.08±0.21	<0.001


RESULTS

Cause of cardiac arrest

	OVERALL	IHCA	OHCA	<i>p-value</i>
Cause of cardiac arrest, n (%)				<u>0.005</u>
Acute coronary syndrome	38 (29.0)	7 (15.6)	31 (36.0)	
Cardiomyopathy	18 (13.7)	7 (15.6)	11 (12.8)	
Pulmonary embolism	5 (3.8)	2 (4.4)	3 (3.5)	
Drug intoxication	4 (3.1)	2 (4.4)	2 (2.3)	
Aortic dissection	6 (4.6)	1 (2.2)	5 (5.8)	
Postcardiotomy	9 (6.9)	9 (20)	0	
Various	15 (11.5)	10 (22.2)	5 (5.8)	
Unknown	36 (27.5)	7 (15.6)	29 (33.7)	

RESULTS

Outcomes



DISCUSSION

ECLS for OHCA

S
U
R
V
I
V
A
L
C
P
C
1-2

**Survival CPC 1-2
10-15%**

Maekawa et al. 49 min. (15.4%)

Kagawa et al. 59 min. (10.2%)

**Survival CPC 1-2
5-10%**

Avalli et al. 77 min. (5.5%)

Pozzi et al. 85 min. (6.1%)

**Survival CPC 1-2
< 5%**

Rousse et al. 110 min. (3.1%)

Le Guen et al. 120 min. (3.9%)

Mégarbane et al. 155 min. (2.1%)

< 60 minutes

60-90 minutes

> 90 minutes

LOW-FLOW

DISCUSSION

ECLS for IHCA

Lower survival to hospital discharge CPC 1-2 than previous published series



**Severe impairment of the renal
and hepatic functions**



Underlying long-standing illness

**Heterogeneous cardiac arrest
etiologies**



**Drug intoxication (4.4%)
Acute coronary syndrome (15.6%)**

**Cardiomyopathies (15.6%)
PCS with unclear cause (13.3%)**

DISCUSSION

ECLS for IHCA vs. OHCA

Author	[Reference]	Survival CPC 1-2 IHCA vs. OHCA	p-value
Kagawa	Resuscitation 2010;81:968-73	26.3% vs. 10.2%	0.07
Wang	Resuscitation 2014;85:1219-24	25.1% vs. 25.8%	>0.05
Dennis	Int J Cardiol 2017;231:131-6	69% vs. 31%	0.87
Ellouze	Artif Organs 2018;42:15-21	20.9% vs. 27.2%	0.76
Avalli	Resuscitation 2012;83:579-83	45.8% vs. 5.5%	<u>0.005</u>

CONCLUSION

ECLS could be considered an ultimate solution in refractory cardiac arrest patients who failed conventional cardiopulmonary resuscitation

IHCA and OHCA patients experienced the same survival to hospital discharge with good neurological outcome after ECLS support

The results of ECLS for refractory OHCA are mainly limited by the low-flow duration

In the setting of refractory IHCA, a better selection of patients is mandatory to improve outcomes and avoid futile support